Albany, NY -- (SBWire) -- 05/21/2018 --Transparency Market Research (TMR) has published a new report titled, "Global Generic Injectables Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025". According to the report, the global generic injectables market is projected to reach over US$ 150 Bn by 2025 at a CAGR of around 13.6% from 2017 to 2025. Asia Pacific is expected to drive the global market. The market in the region is likely to expand at a CAGR of 15% from 2017 to 2025. This is attributed to high consumption of cost-effective generic injectable products, significant patient base, well-established guidelines for the development and manufacture of biosimilars, presence of large number of generic players in the region, and high incidence of cancer and diabetes in the region.

Request a Sample of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=42698

Large molecule injectables segment is anticipated to expand at a rapid pace

The report offers detailed segmentation of the global generic injectables market based on product type, container type, application, end-user, and region. In terms of product type, the market has been bifurcated into large molecule injectables also known as biosimilars and small molecule injectables. The small molecule injectables segment held a major share of the market in 2016. However, the large molecule generic injectables segment is expected to expand at a rapid pace due to strong pipeline of biosimilar products, expected patent expiry of top selling blockbuster biological molecules by 2020, rise in research & development activities in complex therapeutic molecules suitable to be administered in the form of biosimilar injectables, and rapid evolution of regulatory framework to approve biosimilar products globally.

Request a Brochure of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=42698

Dose accuracy and ease of administration make the prefilled syringes segment attractive

The prefilled syringes segment is anticipated to expand at the highest CAGR during the forecast period, due to dose accuracy, ease of administration, prevention of contamination, and increase in technological advancements in the form of multichambered syringes, which reduces chances of drug interactions. Moreover, evolution of advanced drug delivery systems such as auto injectors and injectable pens are expected to increase demand for prefilled syringes during the forecast period.

The oncology segment to account for major share of the market by 2025

The oncology segment constituted major market share in 2016 owing to the rise in incidence of cancer, expected patent loss of majority of oncology injectables products, increase in use of injectable products to target tumors, and surge in research & development activities in oncology biosimilars such as monoclonal antibodies. The oncology therapeutic area is a top priority for product development among leading players in the market. For instance, Biocon is engaged in the clinical trials of oncology biosimilars such as Trastuzumab and Bevacizumab.

View Report @ https://www.transparencymarketresearch.com/generic-injectables-market.html